Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 14/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16705724 | 0.99 | HTR7 (0.54) | HTR7KDM4ERECQLSIGMAR1NOS3 | |
| SCHEMBL14093214 | 0.90 | HTR7 (0.61) | HTR7 | |
| SCHEMBL14093212 | 0.89 | SIGMAR1 (0.50) | HTR7SIGMAR1NOS3NOS1NOS2 | |
| SCHEMBL21671816 | 0.81 | HTR7 (0.64) | HTR7NOS3NOS1NOS2 | |
| SCHEMBL22742672 | 0.80 | HTR7 (0.52) | HTR7NOS3NOS1NOS2 | |
| SCHEMBL16705820 | 0.79 | HTR7 (0.63) | HTR7NOS3NOS1NOS2 | |
| SCHEMBL14093224 | 0.79 | KCNH2 (0.47) | — | |
| SCHEMBL22743123 | 0.79 | HTR7 (0.51) | HTR7NOS3NOS1NOS2 | |
| SCHEMBL23927918 | 0.78 | HTR7 (0.68) | HTR7KDM4E | |
| SCHEMBL14594152 | 0.78 | HTR7 (0.66) | HTR7NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | HTR7 3940/4885KDM4E 1877/4885RECQL 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.